A head-to-head trial in ASTS
August 2019

CHICAGO—Monopar Therapeutics Inc. announced last month that it had begun a clinical collaboration agreement with the Spanish Sarcoma Group (Grupo Español de Investigación en Sarcomas, or GEIS) to conduct a Phase 2 clinical trial assessing Monopar's Camsirubicin in patients with advanced soft tissue sarcoma (ASTS). Therapeutic options for ASTS are limited, and doxorubicin, the most effective first-line drug for this cancer, can only be administered six to eight times due to its potential for heart damage at high cumulative doses. Camsirubicin will be compared with doxorubicin in the randomized, open-label Phase 2 trial, which will be led by GEIS as study sponsor with support from Monopar. According to Dr. Andrew Mazar, chief scientific officer of Monopar, “Camsirubicin has been specifically designed to avoid the irreversible heart toxicity while retaining the anticancer activity of doxorubicin, thus removing the limitations on cumulative dose.”

1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.